Daniel Wendling

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

Dominique Salmon‐Céron, Florence Tubach, Olivier Lortholary et al. · Annals of the Rheumatic Diseases · 2010 · 280 citations

Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.

Daniel Wendling, E Racadot, John Wijdenes · PubMed · 1993 · 277 citations

Joint Inflammation, Immunology, Anti-il-6 Mab +16

The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients

Maxime Dougados, Maria Antonietta D’Agostino, Joëlle Bénessiano et al. · Joint Bone Spine · 2011 · 225 citations

Pain Therapy, Health Sciences, Pain Medicine +10

Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome

Gaëtane Nocturne, Alexandre Virone, Wan‐Fai Ng et al. · Arthritis & Rheumatology · 2015 · 191 citations

Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug

Jacques-Eric Gottenberg, Olivier Brocq, Aleth Perdriger et al. · JAMA · 2016 · 185 citations · Full text